Evidence map›Paper›PMID 22580462›Full record

ArticleCell cycle (Georgetown, Tex.)2012

Regulation of E2F1 by APC/C Cdh1 via K11 linkage-specific ubiquitin chain formation.

Varija N Budhavarapu, Erin D White, Christina S Mahanic, Ligong Chen, Fang-Tsyr Lin, Weei-Chin Lin

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Ubiquitination Links DNA Damage and Repair Signaling to Cancer Metabolism.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. The broken cycle: E2F dysfunction in cancer.Nature reviews. Cancer · 2019
    Review
  14. Article
  15. Article
  16. Article
  17. Regulation of E2F1 Transcription Factor by Ubiquitin Conjugation.International journal of molecular sciences · 2017
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Varija N BudhavarapuSection of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Erin D White
Christina S Mahanic
Ligong Chen
Fang-Tsyr Lin
Weei-Chin Lin
Baylor College of Medicine · USPalmetto Hematology Oncology · USSt. Vincent's Birmingham · USUniversity of Alabama at Birmingham · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
The ATM/E2F1 Pathway in DNA Damage and Growth ControlR01CA100857 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIN, WEEI-CHIN · 2004 to 2019
$4.8M
Therapeutic Targeting of Oncogenic Stress in Cancer TreatmentR01CA138641 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LIN, WEEI-CHIN · 2010 to 2014
$1.5M
Lysophosphatidic Acid Signaling in Ovarian CancerR01CA100848 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIN, FANG-TSYR · 2003 to 2006
$1.0M
NCI NIH HHS 3 P30CA125123-03S5NCI NIH HHS P30 CA125123NCI NIH HHS R01CA100848NCI NIH HHS R01 CA100857NCI NIH HHS R01CA100857NCI NIH HHS R01 CA138641NCI NIH HHS R01CA138641
6 · The paper itself

Abstract

E2F1 is a eukaryotic transcription factor that is known to regulate various cellular pathways such as cell cycle progression, DNA replication, DNA damage responses and induction of apoptosis. Given its versatile roles, a precise and tight regulation of E2F1 is very critical to maintain genomic stability. E2F1 is regulated both at transcriptional and posttranslational levels during cell cycle and upon DNA damage. After S phase, E2F1 is targeted for degradation and is kept at low levels or in an inactive state until the next G 1/S phase transition. Our studies show that APC/C ubiquitin ligase in conjunction with its co-activator Cdh1 (APC/C (Cdh1) ) can downregulate E2F1. We also identify an APC/C subunit APC5 that binds to E2F1 and is essential for E2F1 ubiquitination. We confirm an interaction between E2F1 and Cdh1 as well as an interaction between E2F1 and APC5 both in vivo and in vitro. In vitro GST pull-down assays have mapped the C-terminal 79 a.a. of E2F1 as Cdh1 interacting residues. Ectopically expressed Cdh1 downregulates the expression of E2F1-4. Our studies have also shown for the first time that E2F1 can be modified by K11-linkage specific ubiquitin chain formation (Ub-K11). The formation of Ub-K11 chains on E2F1 is increased in the presence of Cdh1 and accumulated in the presence of proteasome inhibitor, suggesting that APC/C (Cdh1) targets E2F1 for degradation by forming Ub-K11 chains. We also show that the effect of Cdh1 on E2F1 degradation is blocked upon DNA damage. Interestingly, Ub-K11-linked E2F1 accumulates after treatment of DNA damaging agents. The data suggest that DNA damage signaling processes do not inhibit APC/C (Cdh1) to ubiquitinate E2F1. Instead, they block the proteasomal degradation of Ub-K11-linked E2F1, and therefore lead to its accumulation.

Indexed as

Anaphase-Promoting Complex-CyclosomeAntigens, CDApc5 Subunit, Anaphase-Promoting Complex-CyclosomeCadherinsDNA DamageDown-RegulationE2F1 Transcription FactorHEK293 CellsHumansProtein BindingProtein SubunitsRNA InterferenceRNA, Small InterferingS PhaseUbiquitinUbiquitinationANAPC5 protein, humanAnaphase-Promoting Complex-CyclosomeAntigens, CDApc5 Subunit, Anaphase-Promoting Complex-CyclosomeCadherinsCDH1 protein, humanE2F1 Transcription FactorProtein SubunitsRNA, Small InterferingUbiquitinUbiquitin-Protein Ligase Complexes

Identifiers

PMID22580462
PMCPMC3359126
OpenAlexW2025571730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.